ID   RT112rCDDP1000
AC   CVCL_RR17
DR   cancercelllines; CVCL_RR17
DR   Wikidata; Q54951358
RX   PubMed=26055179;
WW   Provider; RCCL; -; https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: Caucasian.
CC   Doubling time: 23.0 hours (PubMed=26055179).
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3690; FGFR3 + HGNC; HGNC:11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1670 ! RT-112
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 10-04-25; Version: 14
//
RX   PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002; PMCID=PMC4487788;
RA   Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M.,
RA   Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.;
RT   "Drug-resistant urothelial cancer cell lines display diverse
RT   sensitivity profiles to potential second-line therapeutics.";
RL   Transl. Oncol. 8:210-216(2015).
//